Currently, TGFβ inhibitors are approved for the treatment of β‐thalassemia and myelodysplastic syndromes, while TGFβR1 inhibitors for advanced solid tumors are in global trials. This evidence concerns the gene TGFBR1 and myelodysplastic syndrome.